| Impact of the delayed initiation of adjuvant chemotherapy in the outcome of triple negative breast cancer Z Morante, R Ruiz, JM Araujo, JA Pinto, G de la Cruz-Ku, ... Clinical Breast Cancer 21 (3), 239-246. e4, 2021 | 45 | 2021 |
| Sintomatología depresiva en pacientes con fibromialgia V Moreno, F Namuche, AE Noriega, M Vidal, C Rueda, J Pizarro, L Vidal Anales de la Facultad de Medicina 71 (1), 23-27, 2010 | 39 | 2010 |
| Oncotype Dx results in patients≤ 40 years: Does age matter? New insights F Namuche, RE Ruiz, ZDM Cruz, D Urrunaga, G Ziegler, R Mantilla, ... Annals of Oncology 29, viii67-viii68, 2018 | 5 | 2018 |
| Abstract GS2-05: Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer Z Morante, R Ruiz, G De la Cruz-Ku, F Namuche, R Mantilla, MG Lujan, ... Cancer Research 79 (4_Supplement), GS2-05-GS2-05, 2019 | 4 | 2019 |
| Ki67 as an important predictor for oncotype dx recurrence score risk groups in early breast cancer F Namuche, RE Ruiz, ZDM Cruz, D Urrunaga, AA Cartagena, ... Annals of Oncology 29, viii68, 2018 | 3 | 2018 |
| The impact of treatment adherence on overall survival in non-metastatic colorectal cancer in Latin American patients. F Namuche, J Leon, CJ Flores Journal of Clinical Oncology 41 (16_suppl), e15644-e15644, 2023 | 2 | 2023 |
| Clinical characteristics and outcomes in cancer patients affected by COVID-19: a study from a Peruvian cancer center R Ruiz, Z Morante, F Namuche, A Arbizu, C Flores, C Vallejos, F Young, ... Onkoresearch 1 (1), 5-13, 2022 | 2 | 2022 |
| Risk factors predicting colorectal cancer recurrence in a Latin American population. J Leon, F Namuche, PC Montenegro, CJ Flores Journal of Clinical Oncology 37 (15_suppl), e15180-e15180, 2019 | 2 | 2019 |
| Abstract P3-08-17: Evaluation of Oncotype DX testing and subsequent treatment choices in the Latin American setting R Ruiz, Z Morante, F Namuche, D Urrunaga, A Aguilar, J Schwarz, ... Cancer Research 79 (4_Supplement), P3-08-17-P3-08-17, 2019 | 2 | 2019 |
| Patterns of metastasis and second primary malignancies (SPM) in colorectal cancer: A perspective from Peru. J Leon, F Namuche, PC Montenegro, CJ Flores Journal of Clinical Oncology 37 (15_suppl), e15068-e15068, 2019 | 1 | 2019 |
| Abstract P6-09-11: Ki67 cut offs and oncotype DX recurrence score in early breast cancer F Namuche, R Ruiz, C Flores, HL Gomez, A Aguilar Cancer Research 78 (4_Supplement), P6-09-11-P6-09-11, 2018 | 1 | 2018 |
| Real-world clinical practice and outcomes in Peruvian patients with advanced EGFR T790M mutation positive NSCLC: A multicenter analysis M Galvez-Nino, K Roque, R Ruiz, F Namuche, V Paitan, T Arrese, ... Cancer Treatment and Research Communications 43, 100906, 2025 | | 2025 |
| Real-world outcomes of osimertinib in Peruvian patients with advanced NSCLC with EGFR T790M-positive: A multi-institutional experience. M Galvez-Nino, K Roque, F Namuche, R Ruiz, V Paitan Amaro, R Coello, ... Journal of Clinical Oncology 42 (16_suppl), e20605-e20605, 2024 | | 2024 |
| Association of treatment regimens with quality of life and overall survival in patients with metastatic colorectal cancer in Peru. F Namuche, J Leon Journal of Clinical Oncology 41 (16_suppl), e15617-e15617, 2023 | | 2023 |
| Oncotype Dx score associated to pathological features to better prognosticate the risk of recurrence for breast cancer patients. F Namuche, R Ruiz, Z Morante, CJ Flores, HL Gomez Journal of Clinical Oncology 39 (15_suppl), e12562-e12562, 2021 | | 2021 |
| Anti-VEGF versus Anti-EGFR in the real world in metastatic colorectal cancer. F Namuche, CJ Flores Journal of Clinical Oncology 38 (15_suppl), e16040-e16040, 2020 | | 2020 |
| Optimizing cut-offs for high neutrophil-to-lymphocyte ratio as poor survival prognostic factor in colorectal cancer. F Namuche, J Leon, PC Montenegro, CJ Flores Journal of Clinical Oncology 37 (15_suppl), e15111-e15111, 2019 | | 2019 |
| Toxicity of chemotherapy in patients with colorectal cancer: The role of age in the Latin American setting. F Namuche, PC Montenegro, J Leon, CJ Flores Journal of Clinical Oncology 37 (15_suppl), e15095-e15095, 2019 | | 2019 |
| Abstract P3-08-22: Oncotype Dx recurrence score risk groups according to Ki67, a predictor to be considered F Namuche, R Ruiz, Z Morante, A Aguilar, H Gomez Cancer Research 79 (4_Supplement), P3-08-22-P3-08-22, 2019 | | 2019 |
| Abstract P3-08-16: Age's importance in early breast cancer: Oncotype Dx results in patients≤ 40 years R Ruiz, F Namuche, Z Morante, A Aguilar, D Urrunaga, G Ziegler, ... Cancer Research 79 (4_Supplement), P3-08-16-P3-08-16, 2019 | | 2019 |
